- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05643248
To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects
A Single Ascending Dose Pilot Study to Assess the Safety, Tolerability and Pharmacokinetics of NEX-20A Given as a Subcutaneous Prolonged-release Injection to Healthy Male Subjects
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Kristine Bäck
- Phone Number: +46 (0)18 100 300
- Email: info@nanexa.se
Study Locations
-
-
-
Uppsala, Sweden
- CTC Clinical Research Consultants AB
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Willing and able to give written informed consent for participation in the study.
- Healthy male subject aged 18 to 65 years, inclusive.
- Clinically normal medical/surgical history, physical findings, vital signs, 12-lead electrocardiograms (ECGs) and safety laboratory values at the time of screening, as judged by the Investigator.
Prospective (male) subjects who are sexually active with female partners must agree to use condoms as well as one of the following highly effective (failure rate <1%) methods of contraception with their partner(s) from 14 days prior to the time of NEX-20A administration until 90 days after the follow-up/end-of-study visit (Visit 14).
- Previous male sterilization, defined as vasectomy conducted at least 6 months prior to screening with appropriate post-vasectomy documentation of the absence of sperm cells in the ejaculate.
- Previous female sterilization, defined as tubal ligation or permanent bilateral occlusion of fallopian tubes.
- Oral (except low-dose gestagen [lynestrenol and norethisterone]), injectable or implanted hormonal contraceptive associated with the inhibition of ovulation.
- Intrauterine device (IUD).
- Intrauterine hormone-releasing system (IUS), e.g., progestin-releasing coil
Exclusion Criteria:
- Body weight outside body mass index 18-30 kg/m2
- Subjects who intend to father a child during the course of the study, i.e., from screening to the final pregnancy check at Visit 15, or whose female partner is pregnant or currently breastfeeding.
Regular smoking or use of nicotine products within the past 6 months prior to screening.
Irregular use of nicotine (e.g., smoking, snuffing, chewing tobacco) less than 3 times/week before the screening visit will be allowed.
- Any intake of alcohol within the previous 24 hours of screening or subsequent study visits, according to alcohol urine tests.
- Any positive screen for drugs of abuse at screening or subsequent study visits.
- Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV), according to diagnostic tests.
- Any use of prescription medication within the previous 14 days of the administration of NEX-20A, at the discretion of the Investigator.
- Any use of over the counter (non-prescription) medication within the previous 48 hours of the administration of NEX-20A, at the discretion of the Investigator, except occasional intake of paracetamol (maximum 2000 mg/day), as well as nasal decongestants without cortisone, antihistamine or anticholinergics.
- Regular use of any herbal remedies, vitamins, minerals, and other food supplements, at the discretion of the Investigator, within the previous 14 days of the administration of NEX-20A.
- Malignancy within the past 5 years, with the exception of in situ removal of basal cell carcinoma.
- Dermatological conditions, tattoos or large scars on the abdomen, thigh or upper arm which, in the opinion of the Investigator, may limit the evaluation of local tolerability.
- History of or current thromboembolic disease, including but not limited to deep vein thrombosis (DVT) and other venous thromboembolisms, untreated hypertension and/or untreated hyperlipidaemia, as judged by the Investigator.
- Family history of thromboembolic disease, specifically first-degree relative with history of or current thromboembolic disease (see exclusion criterion 12), as judged by the Investigator.
- History of or current hematologic disorder, including but not limited to thrombocytopenia and/or neutropenia, as judged by the Investigator.
- History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to lenalidomide or drugs with a similar chemical structure or class or to any other ingredient of the formulation/vehicle.
- History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
- Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks prior to the treatment visit (Visit 2).
- Any planned major surgery within the duration of the study.
After 10 minutes supine rest at the time of screening, any vital signs outside the following ranges:
- Systolic blood pressure: <90 or >140 mmHg, or
- Diastolic blood pressure <50 or >90 mmHg, or
- Pulse <40 or >90 bpm
- Prolonged QTcF (>450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting ECG at the time of screening, as judged by the Investigator.
- Bilirubin >25 µmol/L, alanine aminotransferase (ALT) >1.1 µkat/L, and/or aspartate aminotransferase (AST) >0.75 µkat/L at the time of screening (all values 1x upper limit of normal [ULN]).
- Estimated glomerular filtration rate (eGFR) <80 mL/min/1.73 m2 (determined from plasma creatinine by the revised Lund-Malmö GFR estimating equation) at the time of screening.
- Haemoglobin <130 g/L, absolute neutrophil count (ANC) <1.3x109/L, and/or platelet count <150x109/L at the time of screening.
- History of or current alcohol abuse or excessive intake of alcohol, as judged by the Investigator.
- History of or current drug abuse, as judged by the Investigator.
- History of or current use of anabolic steroids, as judged by the Investigator.
- Participation in any other clinical study and/or treatment with another investigational drug within 90 days of the treatment visit (Visit 2).
- Plasma donation within 1 month of screening or blood donation (or corresponding blood loss) during the last 90 days prior to screening.
- Lack of suitability for participation in the study, for any reason, in the opinion of the Investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
The planned doses are 15 mg for the sentinel subject in cohort 1 and 35 mg for the remaining 2 subjects in cohort 1
|
Subcutaneous prolonged-release injection
|
Experimental: Cohort 2
The planned dose for all 3 subjects in cohort 2 is 70 mg.
|
Subcutaneous prolonged-release injection
|
Experimental: Cohort 3
The planned dose for all 3 subjects in the optional cohort 3 is 100 mg.
|
Subcutaneous prolonged-release injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with a clinical significant change from baseline in the systolic blood pressure at 36 days
Time Frame: From first dose until day 36
|
Measured in mmHg after 10 minutes supine rest.
Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the diastolic blood pressure at 36 days
Time Frame: From first dose until day 36
|
Measured in mmHg after 10 minutes supine rest.
Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the ECG parameter PQ/PR at 36 days
Time Frame: From first dose until day 36
|
Measured in ms in supine position after 10 minutes of rest using an ECG machine.
Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the ECG parameter QRS at 36 days
Time Frame: From first dose until day 36
|
Measured in ms in supine position after 10 minutes of rest using an ECG machine.
Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the ECG parameter QT at 36 days
Time Frame: From first dose until day 36
|
Measured in ms in supine position after 10 minutes of rest using an ECG machine.
Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the ECG parameter QTcF at 36 days
Time Frame: From first dose until day 36
|
Measured in ms in supine position after 10 minutes of rest using an ECG machine.
Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the haematology blood parameters measurements at 36 days
Time Frame: From first dose until day 36
|
Blood samples for the analysis of haematology will be collected through venepuncture or an indwelling venous catheter.
Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the clinical chemistry blood laboratory measurements at 36 days
Time Frame: From first dose until day 36
|
Blood samples for the analysis of clinical chemistry parameters will be collected through venepuncture or an indwelling venous catheter.
Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the coagulation parameters blood laboratory measurements at 36 days
Time Frame: From first dose until day 36
|
Blood samples for the analysis of clinical coagulation parameters will be collected through venpuncture or an indwelling venous catheter.
Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the physical examination of the head at 36 days
Time Frame: From first dose until day 36
|
Physical examination including assessment of the head.
Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the physical examination of eyes at 36 days
Time Frame: From first dose until day 36
|
Physical examination including assessment of the eyes.
Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the physical examination of the ears at 36 days
Time Frame: From first dose until day 36
|
Physical examination including assessment of the ears.Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the physical examination of the nose at 36 days
Time Frame: From first dose until day 36
|
Physical examination including assessment of the nose.Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the physical examination of the throat at 36 days
Time Frame: From first dose until day 36
|
Physical examination including assessment of the throat.
.Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the physical examination of the skin at 36 days
Time Frame: From first dose until day 36
|
Physical examination including assessment of the skin.
Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the physical examination of the thyroid at 36 days
Time Frame: From first dose until day 36
|
Physical examination including assessment of the thyroid.
Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the physical examination of neurological status at 36 days
Time Frame: From first dose until day 36
|
Physical examination including neurological status.
Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the physical examination of the lungs at 36 days
Time Frame: From first dose until day 36
|
Physical examination of the lungs including percussion, inspection, palpation, and auscultation.Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the cardiovascular status of at 36 days
Time Frame: From first dose until day 36
|
Physical examination including inspection, palpation, and auscultation of the heart.
Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the physical examination of the abdomen at 36 days
Time Frame: From first dose until day 36
|
Physical examination including assessments of the abdomen (liver and spleen).
Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the physical examination of lymph nodes at 36 days
Time Frame: From first dose until day 36
|
Physical examination including assessments of the lymph nodes.
Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in the physical examination of extremitets at 36 days
Time Frame: From first dose until day 36
|
Physical examination including assessments of the extremitets.
Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with treatment-related adverse events a assessed by frequency
Time Frame: From first dose until day 36
|
Number of events.Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with treatment-related adverse events a assessed by seriousness
Time Frame: From first dose until day 36
|
Seriousness of adverse events.Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with treatment-related adverse events a assessed by intensity
Time Frame: From first dose until day 36
|
Intensity of adverse events.Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in local tolerability i.e skin reactions assessed by visual inspection.
Time Frame: From first dose until day 36
|
Visual inspection.
Descriptive individual data.
|
From first dose until day 36
|
Number of subjects with a clinical significant change from baseline in local tolerability i.e skin reactions assessed by photography.
Time Frame: From first dose until day 36
|
Photography of injection site.
Descriptive individual data.
|
From first dose until day 36
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum observed plasma concentration (Cmax)
Time Frame: pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
|
Measurement of lenalidomid
|
pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
|
Time of occurrence of Cmax (Tmax)
Time Frame: pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
|
Measurement of lenalidomid
|
pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
|
Area under the plasma concentration vs. time curve (AUC) from time 0 to 8 hours
Time Frame: pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
|
Measurement of lenalidomid
|
pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
|
AUC from time 0 to 12 hours
Time Frame: pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
|
Measurement of lenalidomid
|
pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
|
AUC from time 0 to 7 days
Time Frame: pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
|
Measurement of lenalidomid
|
pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
|
AUC from time 0 to infinity
Time Frame: pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
|
Measurement of lenalidomid
|
pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
|
Terminal elimination half-life
Time Frame: pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
|
Measurement of lenalidomid
|
pre-dose and at 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 12 hours post-dose on Day 1, 24 hours, 48 hours, 72 hours, 120 hours, 168 hours, 240 hours, 336 hours, 408 hours, 504 hours, 576 hours, 672 hours, 744 hours, 840 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Hjalmar Flygt, CTC Clinical Trial Consultants AB
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Multiple Myeloma
Other Study ID Numbers
- NEX-20-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on NEX-20A
-
Resvent Holding USA LTDAvania; Resvent Medical Technology Co., Ltd.Not yet recruitingObstructive Sleep ApneaUnited States
-
Clinical Nutrition Research Centre, SingaporeNanyang Technological UniversityUnknown
-
Cristina Fernandez PerezUnknownSatisfaction | Product Quality
-
Nanexa ABUppsala UniversityCompletedMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)Sweden
-
Ottawa Hospital Research InstituteCSL Behring; Grifols Biologicals, LLCCompleted